What do systematic reviews say?

Quinolone vs aminoglycosides

The review found no eligible studies for this question.

• Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs quinolones

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sinonasal debridement vs no debridement

• Sinonasal debridement versus no debridement for the postoperative care of patients undergoing endoscopic sinus surgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 58 participants
  Low

Topical quinolone vs intramuscular gentamicin

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs oral amoxicillin‐clavulanic acid combination

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

The review found no eligible studies for this question.

• Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

The review found no eligible studies for this question.

• Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 300 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 451 participants
  Moderate

Mepolizumab 100 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 911 participants
  Moderate

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 129 participants
  Very low

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adjuvant chemotherapy vs no chemotherapy

The review found no eligible studies for this question.

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radioembolisation vs chemoembolisation

• Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low